{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vitolins MZ"],"funding":["NCI NIH HHS"],"pagination":["4092-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3816959"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(32)"],"pubmed_abstract":["<h4>Purpose</h4>Hot flashes occur in approximately 80% of androgen-deprived men. Few intervention studies have been conducted to relieve hot flashes in men.<h4>Patients and methods</h4>Eligible androgen-deprived men were randomly assigned to one of four daily regimens (2 × 2 factorial design) for 12 weeks: milk protein powder and placebo pill, venlafaxine and milk protein powder, soy protein powder and placebo pill, or venlafaxine and soy protein powder. The primary end point was hot flash symptom severity score (HFSSS), defined as number of hot flashes times severity. The secondary end point was quality of life (QoL), assessed by using the Functional Assessment of Cancer Therapy-Prostate.<h4>Results</h4>In all, 120 men age 46 to 91 years participated. Most were white (78%) and overweight "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer."],"pmcid":["PMC3816959"],"funding_grant_id":["P30 CA012197","U10 CA 081851-06S2","U10 CA081851-06S2","U10 CA081851"],"pubmed_authors":["Tomlinson WV","Griffin L","Vuky J","Vitolins MZ","Naughton M","Adams PT","Moose D","Lesser GJ","Radford JE","Frizzell B","Shaw EG"],"additional_accession":[]},"is_claimable":false,"name":"Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.","description":"<h4>Purpose</h4>Hot flashes occur in approximately 80% of androgen-deprived men. Few intervention studies have been conducted to relieve hot flashes in men.<h4>Patients and methods</h4>Eligible androgen-deprived men were randomly assigned to one of four daily regimens (2 × 2 factorial design) for 12 weeks: milk protein powder and placebo pill, venlafaxine and milk protein powder, soy protein powder and placebo pill, or venlafaxine and soy protein powder. The primary end point was hot flash symptom severity score (HFSSS), defined as number of hot flashes times severity. The secondary end point was quality of life (QoL), assessed by using the Functional Assessment of Cancer Therapy-Prostate.<h4>Results</h4>In all, 120 men age 46 to 91 years participated. Most were white (78%) and overweight ","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Nov","modification":"2026-04-18T07:10:49.346Z","creation":"2019-03-26T23:49:35Z"},"accession":"S-EPMC3816959","cross_references":{"pubmed":["24081940"],"doi":["10.1200/JCO.2012.48.1432","10.1200/jco.2012.48.1432"]}}